The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.
“Book a Scientist” is a conversation format in which interested parties can “book” 25-minute one-on-one conversations with Leibniz scientists on fixed topics according to the speed dating principle.
Over 30 interested citizens of Regensburg, along with members of the CSU parliamentary group and Mayor Dr. Astrid Freudenstein, visited the Leibniz Institute for Immunotherapy on Tuesday, March 25.
The LIT is expanding its clinical cooperations and welcomes several new LIT Cooperation Groups with their staff. This cooperational format aims to foster scientific synergies and clinical translation with groups that address complementary clinical topics in immunomedicine.
Dr. Dr. Roland Schelker, head of the newly formed Translation Group “T-Cell Fitness” at the LIT and hematology/oncology medical specialist at the University Hospital Regensburg, receives a 75,000 USD G-Rex® Grant by ScaleReady LLC. Pedro Noronha, Research Technician in the LIT Division of Functional Immune Cell Modulation, was intensively involved in the grant application process.
Researchers at the University Hospital Regensburg and the Leibniz Institute for Immunotherapy (LIT) are embarking on an innovative project, ESOSTEM155, aimed at transforming T cell-based cancer therapies. This initiative has been awarded a two-year grant of 460,000 EUR from the National Strategy for Gene and Cell-based Therapies (GCT) funding program.
In January 2025 the first LIT Postdoc Retreat took place in Regensburg.
LIT scientists Dr. Astrid Holzinger, Dr. Markus Barden and Prof. Hinrich Abken give an overview on CARs, TRUCKS and the next generation of T cell therapy in the journal JATROS Hämatologie & Onkologie.
The Leibniz Institute for Immunotherapy (LIT) is pleased to announce the successful completion of Dr. Roland C. Schelker’s second doctoral degree.
Prof. Philipp Beckhove, Scientific Director of the LIT, was guest in the podcast “ImmunVERMITTELT” by Janssen-Cilag GmbH.
Recent work by LIT scientists Prof. Luca Gattinoni and Dr. Jeremy Baldwin published in Cell has generated significant interest both inside and outside the cancer immunology field.
